IMU 4.00% 4.8¢ imugene limited

Ann: Phase 1 CF33-hNIS Study Update - Positive Early Signals, page-24

  1. 273 Posts.
    lightbulb Created with Sketch. 385
    Great news, evidence seems to be building for efficacy in IV administration. 53% stable disease and presumably these results dont include the highest dose cohorts yet
 
watchlist Created with Sketch. Add IMU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.